Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761655 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL916010 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14134551 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL588927 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9917631 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24974550 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12081887 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22444953 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21224008 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31671113 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | disclosed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| EP-3700578-B1 | SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| EP-4637748-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4608453-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-07 | — | — | US | disclosed |
| EP-2029554-B1 | PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING | MEDIBEACON LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8674066-B2 | Peptide capable for binding to rhodium | PANASONIC CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8674066-B2 | Peptide capable for binding to rhodium | PANASONIC CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130267040-A1 | PEPTIDE CAPABLE FOR BINDING TO RHODIUM | PANASONIC CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267040-A1 | PEPTIDE CAPABLE FOR BINDING TO RHODIUM | PANASONIC CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20120100078-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | MALLINCKRODT LLC (US) | 2012-04-26 | — | — | US | disclosed |
| US-8115000-B2 | Pyrazine derivatives and uses thereof in renal monitoring | MALLINCKRODT LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | MEDIBEACON INC. | 2009-08-06 | — | — | US | disclosed |
| EP-2029554-A1 | PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING | Mallinckrodt, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007149479-A1 | PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING | MALLINCKRODT INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | HPGD 4884/4885HTT 3956/4885SMN1; SMN2 2303/4885 |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | ERBB2, EGFR, ERBB3 | HPGD 1830/4885HTT 3186/4885SMN1; SMN2 2915/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | HPGD 4699/4885HTT 2074/4885SMN1; SMN2 2159/4885 |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CNTN1, EPCAM, SLC22A8 | HPGD 3716/4885HTT 4090/4885SMN1; SMN2 957/4885 |
| US-20120100078-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | CYP3A5, GLS, XDH | HPGD 204/4885HTT 4425/4885SMN1; SMN2 3974/4885 |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | GLS, CYP3A5, PYCR1 | HPGD 185/4885HTT 4204/4885SMN1; SMN2 3945/4885 |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | TPM4, TPM3, TPST2 | HPGD 2231/4885HTT 3721/4885SMN1; SMN2 291/4885 |
| US-20130267040-A1 | PEPTIDE CAPABLE FOR BINDING TO RHODIUM | NGLY1, YIPF5, QRFPR | HPGD 2515/4885HTT 3708/4885SMN1; SMN2 4176/4885 |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | FCGR2A, FCGR1A, FCGR3B | HPGD 2546/4885HTT 1793/4885SMN1; SMN2 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.